Pharmaceutical News

Record Second Quarter Results Driven By Market Share Gains Across Major Markets REVLIMID(R) Second Quarter Global Net Product Sales Increased 48% Y/Y VIDAZA(R) Second Quarter Global Net Product Sales Increased 43% Y/Y Non-GAAP Second Quarter Diluted Earnings Per Share Increased 50% Y/Y SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAAP Total Revenue $853 Million Global REVLIMID Net Product Sales Increased 48 Percent to $587 Million Global VIDAZA Net Product Sales Increased 43 Percent to $132 Million Global THALOMID(R) Net Prod...